Oramed Pharmaceuticals Inc. (ORMP)
Nasdaq · Healthcare · Biotechnology
$4.55+1.34%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $189M
- P/E (trailing)
- 1.1
- Dividend yield
- 5.5%
- 52-week range
- $2.09 – $5.47
- 52-week change
- +81.05%
- EPS (trailing)
- $4.13
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $2.0M
- Net income
- $75K
- Operating margin
- −754.4%
- Diluted EPS
- $1.50
- Free cash flow
- −$9.2M
From the company’s annual report on SEC EDGAR.
About Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
Headquarters: New York, United States · oramed.com